EFFICACY OF INTRANASAL ESKETAMINE AS A NOVEL RAPID ANTIDEPRESSANT IN ADULTS WITH TREATMENT- RESISTANT DEPRESSION
DOI:
https://doi.org/10.31004/prepotif.v7i1.11844Keywords:
esketamine, intranasal, treatment-resistant depression, antidepressantAbstract
Major depressive disorder (MDD), the leading cause of disability worldwide is a common and disabling mental health disorder associated with high suicide-related morbidity and mortality rates. Despite the availability of antidepressant therapies, one-third of patients with MDD fail to achieve remission and are considered to have Treatment-Resistant Depression (TRD). Research have found intranasal esketamine, an enantiomer of anesthetic drug called ketamine, as a potential breakthrough in combating treatment resistance and lowering the number of depression-related suicides. However, reviews that cover the potential use of esketamine are still limited. This review aims to summarize the study of esketamine and provide a better insight into its efficacy and safety in TRD patients as a promising end point for TRD remission. Literature sources were taken from journal articles published in the last five years. The databases used were PMC, SAGE Journals, ScienceDirect, Wiley, and ResearchGate. TRD is associated with impaired social functioning and imminent risk of suicidal ideation. The antidepressant effect of intranasal esketamine showed a noteworthy result varying from increased response rate to decreased depression symptoms and suicidal thoughts. Findings from clinical trials indicate that intranasal esketamine is effective and safe in patients with TRD. It implies that esketamine has rapid antidepressant effects in patients with MDD, including TRD and MDSI. Further research regarding esketamine efficacy in some populations such as pediatrics and people with a history of psychosis, is still needed to improve our ability to treat TRD.References
Akil, H., Gordon, J., Hen, R., Javitch, J., Mayberg, H., McEwen, B., Meaney, M. J., & Nestler, E. J. (2018). Treatment resistant depression: A multi-scale, systems biology approach. Neuroscience and Biobehavioral Reviews, 84, 272–288. https://doi.org/10.1016/j.neubiorev.2017.08.019
Ardalan, M., Wegener, G., Rafati, A. H., & Nyengaard, J. R. (2017). S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression. International Journal of Neuropsychopharmacology, 20(3), 247–256. https://doi.org/10.1093/ijnp/pyw098
Bahr, R., Lopez, A., & Rey, J. A. (2019). Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. P and T, 44(6), 340–375.
Bozymski, K. M., Crouse, E. L., Titus-Lay, E. N., Ott, C. A., Nofziger, J. L., & Kirkwood, C. K. (2020). Esketamine: A Novel Option for Treatment-Resistant Depression. Annals of Pharmacotherapy, 54(6), 567–576. https://doi.org/10.1177/1060028019892644
Carreno, F. R., Lodge, D. J., & Frazer, A. (2020). Ketamine: Leading us into the future for development of antidepressants. Behavioural Brain Research, 383. https://doi.org/10.1016/j.bbr.2020.112532
Chaplin, S. (2020). Esketamine nasal spray for treatment?resistant depression. Prescriber, 31(5), 32–34. https://doi.org/10.1002/psb.1845
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., & Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 75(2), 139–148. https://doi.org/10.1001/jamapsychiatry.2017.3739
Degerlund Maldi, K., Asellus, P., Myléus, A., & Norström, F. (2021). Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression. BMC Psychiatry, 21(1). https://doi.org/10.1186/s12888-021-03601-8
Doty, R. L., Popova, V., Wylie, C., Fedgchin, M., Daly, E., Janik, A., Ochs-Ross, R., Lane, R., Lim, P., Cooper, K., Melkote, R., Jamieson, C., Singh, J., & Drevets, W. C. (2021). Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. CNS Drugs, 35(7), 781–794. https://doi.org/10.1007/s40263-021-00826-9
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Ameele, H. Van Den, Preskorn, S., Manji, H., Hough, D., Drevets, W. C., & Singh, J. B. (2019). Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined with a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). International Journal of Neuropsychopharmacology, 22(10), 616–630. https://doi.org/10.1093/ijnp/pyz039
Katz, E. G., Hough, D., Doherty, T., Lane, R., Singh, J., & Levitan, B. (2021). Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Clinical Pharmacology and Therapeutics, 109(2), 536–546. https://doi.org/10.1002/cpt.2024
Katz, E. G., McNulty, P., Levitan, B., Treichler, P., Martynowicz, J., & Jamieson, C. (2022). U.S. Food and Drug Administration’s Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression. Therapeutic Innovation and Regulatory Science, 56(1), 38–46. https://doi.org/10.1007/s43441-021-00340-6
Kaur, M., & Sanches, M. (2021). Experimental therapeutics in treatment-resistant major depressive disorder. Journal of Experimental Pharmacology, 13, 181–196. https://doi.org/10.2147/JEP.S259302
Lucchese, A. C., Sarin, L. M., Magalhães, E. J. M., Del Sant, L. C., B Puertas, C., Tuena, M. A., Nakahira, C., Fava, V. A. R., Delfino, R., Surjan, J., Steiglich, M. S., Barbosa, M., Abdo, G., Cohrs, F. M., Liberatori, A., Del Porto, J. A., Lacerda, A. L. T., & B Andreoli, S. (2021). Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. Journal of Psychopharmacology, 35(2), 142–149. https://doi.org/10.1177/0269881120978398
Mischel, N. A., & Balon, R. (2021). Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers. Journal of Clinical Psychopharmacology, 41(3), 233–235. https://doi.org/10.1097/JCP.0000000000001395
Rathod, S., Denee, T., Eva, J., Kerr, C., Jacobsen, N., Desai, M., Baldock, L., & Young, A. H. (2022). Health-related quality of life burden associated with treatment-resistant depression in UK patients: Quantitative results from a mixed-methods non-interventional study. Journal of Affective Disorders, 300, 551–562. https://doi.org/10.1016/j.jad.2021.12.090
S.Y., S.-A., J.K.E., V., J., K., A.D.I., V. A., D.J., T., M., A. H. R., & R.A., S. (2019). Oral esketamine for treatment-resistant depression: Rationale and design of a randomized controlled trial. BMC Psychiatry, 19(1). http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L629996330%0Ahttp://dx.doi.org/10.1186/s12888-019-2359-1
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020). Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Therapeutic Advances in Drug Safety, 11. https://doi.org/10.1177/2042098620937899
Sanders, B., & Brula, A. Q. (2021). Intranasal esketamine: From origins to future implications in treatment-resistant depression. Journal of Psychiatric Research, 137, 29–35. https://doi.org/10.1016/j.jpsychires.2021.02.020
Sapkota, A., Khurshid, H., Qureshi, I. A., Jahan, N., Went, T. R., Sultan, W., & Alfonso, M. (2021). Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review. Cureus. https://doi.org/10.7759/cureus.17352
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Ruhé, H. G., aan het Rot, M., Kamphuis, J., de Boer, M. K., & Schoevers, R. A. (2022). Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study. BJPsych Open, 8(1). https://doi.org/10.1192/bjo.2021.1059
Wang, S. M., Kim, N. Y., Na, H. R., Lim, H. K., Woo, Y. S., Pae, C. U., & Bahk, W. M. (2021). Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis. Clinical Psychopharmacology and Neuroscience, 19(2), 341–354. https://doi.org/10.9758/cpn.2021.19.2.3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Eldy Eldy, Aurielle Annalicia Setiawan, Sartika Sabhinaya, Pedro Arruda Supinto, Teddy Tjahyanto
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
